<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04548960</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A02018-45</org_study_id>
    <nct_id>NCT04548960</nct_id>
  </id_info>
  <brief_title>OncoSNIPE - Study of Molecular Profiles Associated With the Development of Resistance in Solid Cancer Patients</brief_title>
  <acronym>OncoSNIPE</acronym>
  <official_title>Molecular Profiles Associated With Resistance Development in Cancer Patients. Prospective Exploratory Study From 3 Cancer Locations: TNBC or Locally Advanced or Metastatic, Non-small Cell or Pancreatic or Bronchial Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncodesign SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oncodesign SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Precision medicine is considered to be one of the major issues in patient care. A lot of&#xD;
      research has already proven itself with the implementation of targeted therapies including&#xD;
      immunotherapies offering patients improved response and survival rates. But despite these&#xD;
      major therapeutic advances, resistance to anti-cancer treatment is a major obstacle in the&#xD;
      care of patients. Indeed, to date, many patients die of cancer, 9.6 million deaths worldwide&#xD;
      in 2018. Nowadays, improving understanding of the mechanisms of resistance of cancer cells to&#xD;
      anti-tumor treatments is therefore a major issue. The great diversity of molecular mechanisms&#xD;
      involved in the phenomena of resistance to treatment, whether intrinsic (de novo, or primary)&#xD;
      or acquired (secondary), constitutes a real therapeutic challenge. Indeed, a better&#xD;
      understanding of the mechanisms of resistance would make it possible to explore new&#xD;
      therapeutic strategies making it possible to circumvent these phenomena of escape in&#xD;
      different types of cancer. It is in this context that the OncoSNIPE project was developed.&#xD;
      The objective of this project is to identify early and / or late markers of resistance to&#xD;
      treatment in 3 different pathologies concerned with resistance issues: triple negative breast&#xD;
      cancer or Lum B or locally advanced or metastatic non -small-cell lung cancer or pancreatic&#xD;
      cancer. In this project, in order to best cover the diversity of mechanisms involved in these&#xD;
      resistances, the investigators propose a multidisciplinary approach with clinical, genomic,&#xD;
      transcriptomic and immunological dimensions of the pathology through the data collected from&#xD;
      600 patients (200 for each pathology) for 4 years&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Precision medicine is considered to be one of the major issues in patient care. A lot of&#xD;
      research has already proven itself with the implementation of targeted therapies including&#xD;
      immunotherapies offering patients improved response and survival rates. But despite these&#xD;
      major therapeutic advances, resistance to anti-cancer treatment is a major obstacle in the&#xD;
      care of patients. Indeed, to date, many patients die of cancer, 9.6 million deaths worldwide&#xD;
      in 2018. Nowadays, improving understanding of the mechanisms of resistance of cancer cells to&#xD;
      anti-tumor treatments is therefore a major issue. The great diversity of molecular mechanisms&#xD;
      involved in the phenomena of resistance to treatment, whether intrinsic (de novo, or primary)&#xD;
      or acquired (secondary), constitutes a real therapeutic challenge. Indeed, a better&#xD;
      understanding of the mechanisms of resistance would make it possible to explore new&#xD;
      therapeutic strategies making it possible to circumvent these phenomena of escape in&#xD;
      different types of cancer. It is in this context that the OncoSNIPE project was developed.&#xD;
      The objective of this project is to identify early and / or late markers of resistance to&#xD;
      treatment in 3 different pathologies concerned with resistance issues : triple negative&#xD;
      breast cancer or lum B or locally advanced or metastatic non- small-cell lung cancer or&#xD;
      pancreatic cancer. In this project, in order to best cover the diversity of mechanisms&#xD;
      involved in these resistances, the investigators propose a multidisciplinary approach with&#xD;
      clinical, genomic, transcriptomic and immunological dimensions of the pathology through the&#xD;
      data collected from 600 patients (200 for each pathology) for 4 years.&#xD;
&#xD;
      The patient populations targeted in this study have one common thing: rapid progression of&#xD;
      their pathology, making it possible to obtain models for evaluating markers of early and / or&#xD;
      late responses over the period of follow-up of 2-year post-inclusion patients, and thus&#xD;
      provide the information necessary to understand the resistance mechanisms.&#xD;
&#xD;
      To explore the phenomena of resistance, during the therapeutic response and / or the&#xD;
      progression of the pathology, the investigators will used a multidisciplinary approach&#xD;
      including high-throughput sequencing (Exome-seq and RNAseq) and immunological profil by ELISA&#xD;
      . Patients will have long-term follow-up with different biological samples, at baseline&#xD;
      (blood and biopsy) and at each tumoral evaluation or tumoral progression evaluated by medical&#xD;
      imaging.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>In this study a part of samples (blood and biopsies) will be collected specifically for this study. This is why the study is therefore interventional</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combinatory analysis of genomic, transcriptomic and immunological profile</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Genomic changes associated with early and/or late resistance to treatment given alone or in combination in patients [ Time Frame: Through study completion, up to 2 years ]&#xD;
Transcriptomic changes associated with early and/or late resistance to treatment given alone or in combination in patients [ Time Frame: Through study completion, up to 2 years ]&#xD;
Immunophenotypic changes associated with early and/or late resistance to treatment given alone or in combination in patients [ Time Frame: Through study completion, up to 2 years ]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Clinical data from Baseline until 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Over Survival</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Clinical data from Baseline until 24 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>CANCER</condition>
  <arm_group>
    <arm_group_label>cancer patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>cancer patients To explore the phenomena of resistance during the therapeutic response and/or the progression of the pathology, the investigatorswill used a multidisciplinary approach including high-throughput sequencing (Exome-seq and RNAseq) from blood and tumor samples and immunological profil by ELISA</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cancer patients</intervention_name>
    <description>Blood sample RNA_seq at time of diagnostic, best response and relapse ; Biopsy Exom_seq and RNA_seq at time of diagnostic and relapse Immulogical Profiling at time of diagnostic, best response and relapse</description>
    <arm_group_label>cancer patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. General&#xD;
&#xD;
               -  Adult patient, 18 years of age or older&#xD;
&#xD;
               -  Naive chemo patient&#xD;
&#xD;
               -  Performant status: 0,1 or 2.&#xD;
&#xD;
               -  Life expectancy&gt; 3 months&#xD;
&#xD;
               -  Subject affiliated to a social security and health insurance scheme&#xD;
&#xD;
               -  Subject having dated and signed informed consent&#xD;
&#xD;
               -  For women of childbearing age (negative pregnancy test): effective contraception&#xD;
&#xD;
          2. Pancreatic cancer:&#xD;
&#xD;
               -  Patient receiving a biopsy, as part of the usual care of the patient:&#xD;
&#xD;
                    -  Either from the primary tumor&#xD;
&#xD;
                    -  Either a metastasis for a strong suspicion of locally advanced or metastatic&#xD;
                       pancreatic ductal adenocarcinoma;&#xD;
&#xD;
               -  With advanced or metastatic tumors (liver, lungs, peritoneum, others) that cannot&#xD;
                  benefit from local or locoregional treatment;&#xD;
&#xD;
               -  Presence of target lesion (s) measurable according to RECIST criteria&#xD;
&#xD;
               -  Patient who cannot be treated by surgery or radiotherapy&#xD;
&#xD;
          3. Lung cancer:&#xD;
&#xD;
               -  Patient with histologically proven non-small cell lung cancer&#xD;
&#xD;
               -  Locally advanced stage IIIB or IV&#xD;
&#xD;
               -  Treatment with chemotherapy, targeted therapy, immunotherapy&#xD;
&#xD;
               -  Tissue available after analysis of the usual biomarkers in the event of a&#xD;
                  non-epidermoid tumor&#xD;
&#xD;
               -  Rate of tumor cells observed on biopsies must be ≥ 30%.&#xD;
&#xD;
               -  Presence of measurable target lesion or disease assessable according to RECIST&#xD;
                  criteria&#xD;
&#xD;
          4. Breast cancer:&#xD;
&#xD;
               -  Breast cancer of recent diagnosis, histologically proven.&#xD;
&#xD;
               -  Triple negative breast cancer: negativity of estrogen and progesterone receptors&#xD;
                  in the tumor (&lt;10%), absence of HER2 overexpression according to the IHC&#xD;
                  classification (score 0 or 1+) and / or FISH negative&#xD;
&#xD;
               -  or&#xD;
&#xD;
               -  LumB: RO positive, RP positive or negative, HER2 negative, high proliferation;&#xD;
&#xD;
               -  Stage I to III for triple negative breast cancer (including stage T4d =&#xD;
                  inflammatory cancer), Stage II or III of the UICC classification for LumB&#xD;
&#xD;
               -  Non-metastatic patient (M0 according to TNM classification)&#xD;
&#xD;
               -  Rate of tumor cells observed on biopsies must be ≥ 30%&#xD;
&#xD;
               -  Patient who cannot be treated exclusively by surgery or radiotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General&#xD;
&#xD;
          -  History of chemotherapy (except adjuvant completed for more than at least 6 months) or&#xD;
             radiotherapy&#xD;
&#xD;
          -  Patient whose monitoring and treatment will not be carried out in the study health&#xD;
             establishments;&#xD;
&#xD;
          -  Tumor not histologically proven;&#xD;
&#xD;
          -  Life expectancy of less than 3 months&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Refusal to participate in the trial&#xD;
&#xD;
          -  Persons deprived of their liberty, persons under guardianship or curatorship&#xD;
&#xD;
          -  Inability to submit to the medical follow-up of the test for social or psychological&#xD;
             reasons&#xD;
&#xD;
          -  No affiliation to a social security scheme or state medical aid (AME) or universal&#xD;
             medical coverage (CMU)&#xD;
&#xD;
          -  Any condition for which participation in the protocol would present a risk or which&#xD;
             would not make it possible to comply with the requirements of the protocol according&#xD;
             to the investigator&#xD;
&#xD;
          -  History of other cancers in the last 5 years except cervical cancer and skin cancer of&#xD;
             the basal or epidermoid cells treated&#xD;
&#xD;
          -  Known HIV seropositivity Specific&#xD;
&#xD;
        Pancreatic cancer:&#xD;
&#xD;
          -  Other histologies: neuroendocrine cancer, acinar cancer, pancreatic metastasis of&#xD;
             another cancer&#xD;
&#xD;
          -  Patient who cannot benefit from chemotherapy (Performans status (PS) 3 - 4);&#xD;
&#xD;
          -  Other progressive cancer during the management of pancreatic cancer;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>FRANCOIS GHIRINGHELLI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Georges François Leclerc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PHILIPPE GENNE, PhD</last_name>
    <phone>+33 3 80 78 82 60</phone>
    <email>PMONGIN@ONCODESIGN.COM</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SEBASTIEN VACHENC</last_name>
    <phone>+33 3 80 78 82 60</phone>
    <email>SVACHENC@ONCODESIGN.COM</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <state>Auvergne-Rhône-Alpes</state>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHRISTELLE DE LA FOUCHARDIERE, MD</last_name>
    </contact>
    <investigator>
      <last_name>CHRISTELLE DE LA FOUCHARDIERE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Besancon</name>
      <address>
        <city>Besancon</city>
        <state>Bourgogne Franche Comte</state>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>FERNANDO BAZAN, MD</last_name>
    </contact>
    <investigator>
      <last_name>FERNANDO BAZAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CGFL</name>
      <address>
        <city>Dijon</city>
        <state>Bourgogne Franche Comte</state>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ISABELLE DESMOULINS, MD</last_name>
    </contact>
    <investigator>
      <last_name>ISABELLE DESMOULINS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <state>Bourgogne Franche Comte</state>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PASCAL FOUCHER, MD</last_name>
    </contact>
    <investigator>
      <last_name>PASCAL FOUCHER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <state>Grand EST</state>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christelle CLEMENT-DUCHÊNE, MD</last_name>
    </contact>
    <investigator>
      <last_name>CHRISTELLE CLEMENT-DUCHÊNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Godinot</name>
      <address>
        <city>Reims</city>
        <state>Grand EST</state>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AUDE-MARIE SAVOYE, MD</last_name>
    </contact>
    <investigator>
      <last_name>AUDE-MARIE SAVOYE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <state>Grand EST</state>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MICHELE BEAU-FALLER, MD</last_name>
    </contact>
    <investigator>
      <last_name>MICHELE BEAU-FALLER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <state>Nouvelle-Aquitaine</state>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NICOLAS ISAMBERT, MD</last_name>
    </contact>
    <investigator>
      <last_name>NICOLAS ISAMBERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>DAVID TOUGERON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <state>Paca</state>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MARINE GILABERT, MD</last_name>
    </contact>
    <investigator>
      <last_name>MARINE GILABERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <state>Paris</state>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PHILIPPE LEVY, MD</last_name>
    </contact>
    <investigator>
      <last_name>PHILIPPE LEVY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NICOLAS GIRARD, MD</last_name>
    </contact>
    <investigator>
      <last_name>NICOLAS GIRARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.oncodesign.com/en/our-technologies/oncosnipe-technology</url>
    <description>OncoSNIPE Program description</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 6, 2020</study_first_submitted>
  <study_first_submitted_qc>September 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Resistance</keyword>
  <keyword>Markers</keyword>
  <keyword>Exome</keyword>
  <keyword>Transriptome</keyword>
  <keyword>Immunological Profil</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

